1. Home
  2. LIXT vs GNLN Comparison

LIXT vs GNLN Comparison

Compare LIXT & GNLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • GNLN
  • Stock Information
  • Founded
  • LIXT 2005
  • GNLN 2005
  • Country
  • LIXT United States
  • GNLN United States
  • Employees
  • LIXT N/A
  • GNLN N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • GNLN Durable Goods
  • Sector
  • LIXT Health Care
  • GNLN Consumer Discretionary
  • Exchange
  • LIXT Nasdaq
  • GNLN Nasdaq
  • Market Cap
  • LIXT 12.4M
  • GNLN 12.9M
  • IPO Year
  • LIXT N/A
  • GNLN 2019
  • Fundamental
  • Price
  • LIXT $4.47
  • GNLN $3.30
  • Analyst Decision
  • LIXT
  • GNLN
  • Analyst Count
  • LIXT 0
  • GNLN 0
  • Target Price
  • LIXT N/A
  • GNLN N/A
  • AVG Volume (30 Days)
  • LIXT 121.5K
  • GNLN 92.0K
  • Earning Date
  • LIXT 08-07-2025
  • GNLN 08-14-2025
  • Dividend Yield
  • LIXT N/A
  • GNLN N/A
  • EPS Growth
  • LIXT N/A
  • GNLN N/A
  • EPS
  • LIXT N/A
  • GNLN N/A
  • Revenue
  • LIXT N/A
  • GNLN $7,954,000.00
  • Revenue This Year
  • LIXT N/A
  • GNLN $1,541.21
  • Revenue Next Year
  • LIXT N/A
  • GNLN N/A
  • P/E Ratio
  • LIXT N/A
  • GNLN N/A
  • Revenue Growth
  • LIXT N/A
  • GNLN N/A
  • 52 Week Low
  • LIXT $0.64
  • GNLN $2.84
  • 52 Week High
  • LIXT $5.14
  • GNLN $5,944.50
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 58.29
  • GNLN 42.22
  • Support Level
  • LIXT $3.20
  • GNLN $3.21
  • Resistance Level
  • LIXT $4.60
  • GNLN $3.39
  • Average True Range (ATR)
  • LIXT 0.51
  • GNLN 0.29
  • MACD
  • LIXT 0.06
  • GNLN 0.12
  • Stochastic Oscillator
  • LIXT 78.53
  • GNLN 21.52

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About GNLN Greenlane Holdings Inc.

Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.

Share on Social Networks: